Bausch + Lomb launches Miebo

Miebo is the first and only prescription eye drop that directly targets tear evaporation.
Sandra Levy
Senior Editor
Sandra Levy profile picture

Bausch + Lomb is introducing Miebo (perfluorohexyloctane ophthalmic solution) for the treatment of the signs and symptoms of dry eye disease. Miebo is the only prescription eye drop approved for DED that directly targets tear evaporation, the company noted.

“More and more Americans are suffering from dry eye disease, due in large part to today’s multi-screen lifestyles,” said Andrew Stewart, president of global pharmaceuticals and international consumer at Bausch + Lomb. “With Miebo, eye care professionals now have a prescription eye drop that directly addresses tear evaporation, the leading cause of dry eye disease.”

[Read more: Bausch + Lomb to acquire Xiidra from Novartis]

DED affects more than 38 million Americans, with approximately nine in 10 experiencing evaporative dry eye. When not addressed, tear evaporation may lead to worsening of the condition by triggering a cycle of inflammation and ocular surface damage. MIEBO is a single ingredient, water-, preservative- and steroid-free prescription eye drop that spreads quickly and comfortably. It is designed to address the signs and symptoms of DED by reducing tear evaporation at the ocular surface, the company said.